Pay in 4 interest-free payments of $23.75 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
InChi: InChI=1S/C24H32N4O6/c1-13(2)9-18(23(32)27-17(20(30)12-29)10-14-7-8-25-22(14)31)28-24(33)19-11-15-16(26-19)5-4-6-21(15)34-3/h4-6
4 mg/kg MK-8776 S-isomer is sufficient to induce the γ-H2AX biomarker while 8 mg/kg leads to enhanced tumor pharmacodynamic and regression responses relative to gemcitabine or MK-8776 S-isomer alone
a new class of potential cancer therapeutics
and several cancer lineages in vitro
InChi: InChI=1S/C20H16Br2N2O3S/c21-16-7-9-17(10-8-16)24-20(25)15-6-11-18(22)19(12-15)28(26
ENMD-2076 ohesperidin dihydrochalcone InChi: InChI=1S/C24H32N4O6/c1-13(2)9-18(23(32)27-17(20(30)12-29)10-14-7-8-25-22(14)31)28-24(33)19-11-15-16(26-19)5-4-6-21(15)34-3/h4-6ENMD 2076 is an orally active, Aurora A angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD 2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over expressed in human cancers. ENMD 2076 also targets the VEGFR, Flt 3 and FGFR3 kinases which have been
US$ 1585.54
US$ 40.99
US$ 1971.20
US$ 3758.76
US$ 1709.16
US$ 807.08
US$ 1559.35
US$ 682.77
US$ 9101.78
US$ 8973.25